Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.
Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff.
The FDA has approved Opdivo plus Yervoy for the first-line treatment of MSI-H/dMMR colorectal cancer, supported by the Phase 3 CheckMate-8HW trial results.
U.S. District Judge Edgardo Ramos in Manhattan said the plaintiffs failed to show that Bristol Myers and Celgene Corp violated the federal Sherman antitrust law.
Bristol-Myers Squibb Co. traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer immunotherapy.
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.
As volatility rattles tech giants, investors are rotating into value stocks for stability and upside. Discover why this five-letter word could be the key to winning in 2025.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
